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The size of a lymphocyte population is primarily determined by a dynamic equilibrium between cell
proliferation and death. Hence, lymphocyte recirculation between the peripheral blood and lymphoid tissues
is a key determinant in the maintenance of cell homeostasis. Insights into these mechanisms can be gathered
from large-animal models, where lymphatic cannulation from individual lymph nodes is possible. In this study,
we assessed in vivo lymphocyte trafficking in bovine leukemia virus (BLV)-infected sheep. With a carboxyfluo-
rescein diacetate succinimidyl ester labeling technique, we demonstrate that the dynamics of lymphocyte
recirculation is unaltered but that accelerated proliferation in the lymphoid tissues is compensated for by
increased death in the peripheral blood cell population. Lymphocyte homeostasis is thus maintained by
biphasic kinetics in two distinct tissues, emphasizing a very dynamic process during BLV infection.
In vertebrates, continuous recirculation of lymphocytes from
blood through tissues and lymph nodes is critical for protection
of the host during pathological inflammatory processes, as well
as physiological emigration of lymphocytes that participate in
immune surveillance (1, 4, 6, 11, 16, 33). The network of
exchange between blood and lymph through the lymph node is
absolutely required to maintain normal cell homeostasis. The
presence of homeostatic control of lymphocyte numbers en-
sures an equilibrium where cell production equals cell loss. In
an immune system where lymphocyte production is continuous
and the total number of cells is constant, each newly produced
lymphocyte can only survive if another one dies; i.e., the rate of
peripheral cell renewal depends on the life span of peripheral
cells. However, the life expectancy of a lymphocyte is not an
intrinsic property of the cell but is determined by factors such
as the environment, viral infections, and the presence or ab-
sence of another, competing, cell population. We previously
studied lymphocyte homeostasis, more particularly, lympho-
cyte proliferation and death, in different animal models of
chronic leukemia, including sheep infected by the bovine leu-
kemia virus (BLV) (7–9). In this model, proliferation was es-
timated by intravenous injection of bromodeoxyuridine
(BrdU), a thymidine analog which is incorporated into the
newly synthesized DNA via the pyrimidine salvage pathway.
Although BrdU uptake by cells might occur in blood, its in-
corporation is thought to occur mainly, if not exclusively, in
lymphoid tissues such as the lymph nodes, the spleen, or the
bone marrow (7). By this approach, the estimated B-cell pro-
liferation rates in infected and control sheep were 0.020 day1
and 0.011 day1, respectively, meaning that 2.0 and 1.1% of
the cells were produced by proliferation in 1 day. In contrast,
the death rates of BrdU-labeled cells were not significantly
different between the two categories of animals (average death
rate, 0.089 day1 versus 0.094 day1, respectively). The imbal-
ance created by the net increase in proliferation in the absence
of compensating cell death was estimated at 7% growth in a
day (7), leading to a theoretical very fast doubling of the cell
population. However, this considerable increase in lymphocyte
numbers is, in fact, not observed in vivo. Therefore, other
processes, including a reduction of cell recirculation through
the lymph node, as well as massive elimination of cells in
secondary lymphoid tissues (28, 29), could play a role in main-
taining homeostasis.
The goal of this study was to test these hypotheses by track-
ing B cells from blood to lymph and back from lymph to blood.
The strategy that we used was based on a single intravenous
injection of carboxyfluorescein diacetate succinimidyl ester
(CFSE) into BLV-infected sheep. In vivo administration of the
dye has achieved a blood leukocyte labeling index of 95%,
making it feasible to track lymphocyte migration through the
lymph node in vivo (3, 27). While most studies of lymphocyte
recirculation and homing have been done with rodents (12),
sheep offer the opportunity to study recirculation of lympho-
cytes through tissues by direct cannulation of individual lym-
phatic vessel (15). Therefore, lymphatic cannulation of sheep,
combined with CFSE injection, provided quantitative and
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qualitative physiological measurements of the recirculation
and death of lymphocytes through lymph nodes for extended
periods of time in normal and pathological situations.
MATERIALS AND METHODS
Cannulation of efferent lymphatics. Eleven sheep were kept under controlled
conditions at the Veterinary and Agrochemical Research Centre (Machelen,
Belgium). Five animals (2147, 2149, 2152, 4533, and 4534) were used as unin-
fected controls, whereas sheep 107, 1095, 2091, 2158, 4535, and 4536 were
experimentally infected with a BLV wild-type cloned provirus (strain 344) as
described previously (31). Table 1 illustrates the percentages of B cells in the
blood and lymph, as well the type of cannulated lymph node (prescapular or
mesenteric), in the experimental sheep. Total leukocyte counts were determined
by using a Coulter counter ZN, and the number of lymphocytes was estimated
under a microscope after staining with May-Gru¨nwald-Giemsa. In parallel, the
serum of each sheep was analyzed for BLV seropositivity by immunodiffusion
and enzyme-linked immunosorbent assay techniques (25). Cannulae were surgi-
cally established in intestinal or prescapular efferent lymphatics to allow chronic
sampling of lymph as previously described (34). Briefly, sheep were fasted for
24 h preceding surgery and anesthetized by intravenous injection of pentobar-
bital sodium (Nembutal; Abbott) or fluothane (Covely) with closed-circuit an-
esthetic equipment. Aseptic surgical techniques were used throughout the sur-
gery. Silicone (Vygon) or vinyl (Scientific Commodities) catheters were filled
with heparin (Sigma) and positioned in efferent lymphatic vessels. Following
surgery, animals were allowed to recover for at least 24 h prior to cell collection.
Lymph samplings were performed arbitrarily at short intervals of time in the
beginning of the experiment in order to precisely define the best kinetics of
CFSE-labeled cell migration. All animals were housed in metabolism cages
during lymph collection and allowed free access to food and water during the
experiment. Handling of animals and experimental procedures were conducted
in accordance with institutional and national guidelines for animal care and use.
In vivo CFSE cell labeling and immunophenotyping. Twenty-five milligrams of
CFSE dissolved in 4 ml of dimethyl sulfoxide and 40 l of heparin (1,000 U/ml)
was directly injected into the peripheral blood via the jugular vein in order to
label blood leukocytes (27). At regular intervals of time, blood was collected by
jugular venipuncture and peripheral blood mononuclear cells (PBMCs) were
isolated by Percoll gradient centrifugation (Sigma). Lymph was collected in
sterile bottles attached to bottle holders pasted to the skin of animals and
containing 1,000 U of heparin. Lymphocytes were harvested by low-speed cen-
trifugation, and cell viability was estimated by trypan blue dye exclusion.
Cells were labeled with monoclonal antibodies directed against surface immu-
noglobulin M (anti-sIgMs, clone 1H4, mouse IgG1; Pig45A2, mouse IgG2b),
CD4 (ST4, mouse IgG1), CD5 (CC17, mouse IgG1), CD8 (CC58, mouse IgG1),
CD11b (CC125, mouse IgG1),  T cells (86D, mouse IgG1), CD21 (GB25A,
mouse IgG1), and L-selectin (DU1-29, IgG1) provided by C. Howard (Institute
for Animal Health, Compton, United Kingdom) and by one of us (I.S.-C.) or
obtained from VMRD Inc. Cells were then labeled with a rat anti-mouse IgG1
phycoerythrin-conjugated antibody or with a rat anti-mouse IgG2ab peridinin
chlorophyll protein (PerCp) antibody (Becton Dickinson Immunocytometry Sys-
tems). For detection of the p24 major capsid antigen, PBMCs were cultivated at
37°C in a 5% CO2–air atmosphere in RPMI 1640 medium supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 U of penicillin, and 100 g of
streptomycin per ml (Sigma). After 24 h of culture, PBMCs were collected and
washed once with phosphate-buffered saline–0.5% bovine serum albumin. The
cells were fixed and permeabilized with the IntraStain reagent (DAKO). Internal
detection of the p24 viral protein was performed by sequential incubation with
4G9 monoclonal antibody and a rat anti-mouse IgG1 phycoerythrin conjugate
(Becton Dickinson Immunocytometry Systems). Finally, cells were analyzed in
combination with CFSE by flow cytometry on a Becton Dickinson FACScan flow
cytometer. Ten thousand events were collected for each sample, and data were
analyzed with the CellQuest software (Becton Dickinson Immunocytometry Sys-
tems).
Mathematical model. To estimate the proliferation and disappearance rates of
different cell populations, a mathematical model was constructed (details were
provided by Asquith et al. [2]). Briefly, the model uses two pieces of data from
the flow cytometry analyses, i.e., the proportion of CFSE cells (P) and the ratio
of the mean fluorescence intensity of the CFSE population to the CFSE
population (I), to estimate the rate of proliferation and the rate of death of
CFSE-labeled B lymphocytes. To develop the model, we first estimated the
number of divisions (halving of fluorescence) between an average CFSE cell
and an average CFSE cell at time zero. It was found to be five for sheep 2152,
4533, 4534, 2091, 2158, 4535, and 4536 and six for sheep 2147. The model for five
divisions is x0  (p  d)x0, x1  2px0  (p  d)x1, x2  2px1  (p  d)x2, x3 
2px2  (p  d)x3, x4  2px3  (p  d)x4, and x5  2px4  (p  d)x5  	, where
xi is the proportion of B cells that have undergone i divisions since CFSE
labeling. In the model, the cells in the x5 category are CFSE (either because
they have divided five times since labeling and therefore lost their fluorescence
or because they were not labeled by the initial injection). The average prolifer-
ation rate of cells is p, the average disappearance rate is d, and the average
replacement rate is 	. These equations can be solved analytically and then used
to find expressions for I, the ratio of the mean fluorescence intensity (MFI) of the
CFSE population to the CFSE population, and P, the proportion of CFSE
cells, as follows:
I
Jx0 J/2x1 J/4x2 J/8x3 J/16x4






24 24pt 12p2t2 4p3t3 p4t4
3 6pt 6p2t2 4p3t3 2p4t4
P
x0 x1 x2 x3 x4
x0 x1 x2 x3 x4 x5
 Fe
pdt
1  2pt 2p2t2 4/3p3t3 2/3p4t4
Here, J is the MFI of the CFSE label in undivided cells and F is the proportion
TABLE 1. Overall design of the lymph node cannulation studya
Status and sheep Cannulated lymphnode
% of B cells ( SD) Proviral load
(% infected cells)Blood Lymph
Uninfected
2149 Mesenteric 25.60  2.91 11.73  1.18 0
2152 Mesenteric 37.57  2.69 32.83  2.86 0
4533 Prescapular 22.95  1.59 7.93  1.94 0
4534 Prescapular 23.10  4.35 4.62  1.27 0
2147 None 8.05  1.50 ND 0
Infected
107 Mesenteric 75.37  1.47 12.81  1.96 ND
1095 Prescapular 28.10  1.08 16.96  3.24 ND
4535 Prescapular 41.20  2.56 10.71  1.42 17.8
4536 Prescapular 51.43  4.59 9.13  1.49 6.8
2091 None 53.76  4.71 ND 70.1
2158 None 57.60  3.24 ND ND
a The coordinates, type of cannulated lymph node, and percentages of B cells are indicated with regard to the infection status of sheep. Mean percentages of B
lymphocytes were determined by flow cytometry in three independent experiments. The proviral loads (in percentages of infected cells considering that all cells contain
a single proviral copy) were determined by real-time PCR. ND, not determined.
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of peripheral blood B cells labeled by the initial injection. These formulas were
fitted to the experimental data by nonlinear regression, and lymphocyte kinetics
were estimated.
RESULTS
B lymphocytes from BLV-infected and control sheep recir-
culate at similar rates. The kinetics of the whole peripheral
blood population can be investigated by in vivo administration
of CFSE (i) because cells are labeled regardless of their divi-
sion state; (ii) because CFSE labels all of the cells in the whole
peripheral blood; (iii) because of instability of the succinimidyl
ester moiety, initial labeling by CFSE ends within a few min-
utes; and (iv) because insufficient CFSE reaches the lymph
nodes to directly label cells in this compartment (27). Cell
migration from the peripheral blood through individual lymph
nodes can then be identified by placing indwelling catheters
into the efferent lymphatic vessels and subsequent analysis by
flow cytometry. We first verified that no CFSE-labeled cells
were detectable in the efferent lymph immediately after CFSE
injection (see Fig. S1 in the supplemental material).
Figure 1A illustrates an example of B-cell–CFSE dual flow
cytometry analysis performed on lymph recovered from a
BLV-infected sheep (4535) and a control (4534) sheep at 2, 22,
and 94 h after CFSE injection. The percentages of B CFSE
cells in the total B-cell population were low at 2 h post CFSE
injection, increased at 22 h, and stabilized later on.
To extend these observations, the recirculation kinetics of
CFSE-labeled blood B cells was determined by this approach
in four BLV-infected and four control sheep (Fig. 1B). The
data shown for sheep 4533, 4534, 4535, and 4536 result from
prescapular cannulation; the data for sheep 2149, 2152, and
107 were obtained with mesenteric lymph; and sheep 1095 was
cannulated in both the prescapular and mesenteric lymph
nodes. Although the appearance rate of CFSE B lymphocytes
in the efferent lymph slightly varied in different animals, the
percentage of labeled cells consistently reached an equilibrium
level of approximately 3 to 7% after about 20 to 30 h. These
recirculation kinetics in control sheep are thus in accordance
with previous reports assuming that the maximum recovery of
all subsets of lymphocytes in efferent lymph is about 24 h (27,
33). However, we could not observe a significant difference
between the kinetics of CFSE-labeled cell exit from the lymph
nodes independently of the cannulated lymph node. Impor-
tantly, the recirculation rates in BLV-infected sheep did not
significantly differ from those in the controls (as determined by
a two-tailed Student t test at 26 h; Fig. 1C). Furthermore, we
analyzed the change in the label over time in the lymph by
fitting a growth model with two parameters—the rate of in-
crease of the label (a) and the equilibrium value of the label (k)
(Fig. 1D). Finally, neither the rate of recirculation of labeled B
cells to the lymph nor the equilibrium value of labeled cells in
the lymph varied between BLV-infected and uninfected sheep
(P  0.39 and P  0.57 for a and k, respectively, according to
the Wilcoxon-Mann-Whitney two-tailed test).
Peripheral blood B cells from BLV-infected and control
sheep exhibit different CFSE kinetics. If recirculation through
lymph nodes is not involved, other regulatory processes, such
as higher death rates of the peripheral blood B-lymphocyte
population, might compensate for a global excess of prolifer-
ation in BLV-infected sheep. To test this hypothesis, CFSE
kinetic profiles of peripheral blood B lymphocytes were com-
pared in BLV-infected and control sheep. We first verified that
CFSE injection indeed leads to very efficient fluorescent label-
ing of PBMCs in vivo (Fig. 2A), as reported in a previous paper
(27). After reaching a labeling index of 95% 1 min after
injection, the percentages of CFSE-labeled cells within the
PBMC population rapidly dropped at 2 h (illustrated in panel
A for a noninfected sheep). Flow cytometry analyses with
PBMCs isolated from a BLV-infected (2091) and a control
(2147) sheep at days 0, 1, 6, and 34 after CFSE injection are
illustrated in Fig. 2B. At day 1, approximately half of the B
cells were CFSE (51.6 and 46.0% in the control and BLV-
infected sheep, respectively; Fig. 2B). The percentage of
CFSE-labeled B cells in blood then decreased more quickly in
the infected sheep than in the uninfected animal (4.6% and
15.8% at day 34 for the infected and uninfected sheep, respec-
tively). A similar difference in kinetics was observed in two
other BLV-infected sheep (4535 and 4536) and two controls
(4533 and 4534) (Fig. 2C). Indeed, the percentages of CFSE-
labeled B cells reached a level below 5% around days 27 to 42
for BLV-infected sheep (2091, 4535, and 4536), whereas the
same value was obtained only after 83 days in the controls
(2147, 4533, and 4534) (arrows in Fig. 2C). Interestingly, the
decrease in CFSE peripheral blood B cells was thus consis-
tently faster in BLV-infected animals than in controls.
A CD11b subpopulation accounts for the difference in CFSE
kinetics in BLV-infected sheep. To test whether this difference
in kinetics was associated with a particular cell phenotype,
CFSE labeling was evaluated in four subsets of B cells express-
ing L-selectin, CD21, CD5, or CD11b. These markers were
FIG. 1. B-cell trafficking through the lymph node. (A) The efferent lymphatic vessels from the prescapular lymph nodes of a BLV-infected
(4535) and a control (4534) sheep were surgically cannulated, allowing chronic sampling of lymph. Animals were injected intravenously with 25
mg of CFSE. At regular intervals of time (2, 22, and 94 h), lymph was collected and B cells were labeled with the anti-IgM 1H4 monoclonal antibody
in association with a phycoerythrin conjugate. Ten thousand cells were then analyzed by two-color flow cytometry (x axis  CFSE; y axis  B
lymphocytes). The percentages of CFSE B cells within the total B-lymphocyte population are indicated in the upper right quadrants. (B) Lymph
samples from four BLV-infected (107, 1095, 4535, and 4536) and four control (2149, 2152, 4533, and 4534) sheep were continuously collected at
regular intervals of time (in hours) post CFSE injection, and the percentages of CFSE B cells within the total B-cell population were determined.
A vertical line is placed at 24 h. (C) Graphic distribution of the percentages of CFSE B cells in efferent lymph recovered at 26 h after CFSE
injection. Individual values (BLV-infected [Œ, 107; }, 1095; ■, 4535; F, 4536] and uninfected [‚, 2149;, 2152;, 4533; E, 4534] sheep) and mean
values (black lines) are represented. NS means no statistically significant difference by the Student t test. (D) Schematic representation of the
change in label over time in the lymph. The model contains two parameters, i.e., the rate of increase in the label (a) and the equilibrium value
of the label (k). Neither the rate of recirculation of labeled B cells to the lymph nor the equilibrium value of labeled cells in the lymph varied
between BLV-infected and uninfected sheep (P 0.39 and P 0.57 for a and k, respectively, according to the Wilcoxon-Mann-Whitney two-tailed
test).
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selected primarily because the migration competence of B lym-
phocytes correlates with the surface expression of L-selectin
and CD21 mediating subsequent integrin-dependent adher-
ence (14, 35). Moreover, BLV preferentially replicates in
CD5 and CD11b B lymphocytes, although cells negative for
these receptors are also less efficient targets for the virus (5,
22). After CFSE injection, PBMCs were isolated from BLV-
infected or control sheep; labeled sequentially with an anti-
IgM antiserum and with anti-L-selectin, anti-CD21, anti-CD5,
or anti-CD11b monoclonal antibodies; and then analyzed by
three-color flow cytometry. Importantly, all of the cell popu-
lations in the peripheral blood were CFSE labeled with effi-
ciencies of 95% (data not shown). For three out of the four
markers (i.e., L-selectin, CD21, and CD5), the CFSE profiles
were the same for marker-positive and marker-negative cells
and the difference between the CFSE profiles of uninfected
and infected animals was maintained (Fig. 3). In contrast, the
kinetics of CD11b B lymphocytes was similar between BLV-
infected and control samples (and particularly at day 26 [ar-
row]), indicating that the expression of the CD11b integrin
accounted for the particular CFSE profile of infected sheep.
The death rate of peripheral blood B cell is increased in
BLV-infected sheep. A reduction in the proportion of CFSE
lymphocytes can be due either to cell death or to label dilution
below the threshold of detection due to proliferation. These
parameters could be quantified assuming that the fluorescence
intensity of the CFSE label is halved upon cell division. A
mathematical model was designed by incorporating a relation-
ship between I (the ratio of the mean fluorescence intensities
of B CFSE and B CFSE populations) and P (the pro-
portion of CFSE B cells) (Asquith et al., unpublished data).
By fitting this model to the CFSE data (theoretical fits, Fig. 4)
from four BLV-infected and four control sheep, the average
proliferation rate (p) and death rate (d) of the CFSE B-cell
population could be estimated (Table 2). The proliferation
rate is an estimate of the proportion of B cells that divide in 1
day (e.g., in sheep 2147, if p  0.049 day1 then approximately
4.9% of the CFSE B lymphocytes proliferate in 1 day). Sim-
ilarly, the death rate (0.079 day1) is the proportion of labeled
B cells that disappear from the blood of the animal in 1 day.
On the basis of the measured incorporation levels, the prolif-
eration and death rates were calculated for all of the sheep
studied (Table 2). The mean proliferation rates were not sig-
nificantly different in the two categories of animals (0.029 
0.017 for the controls and 0.039  0.003 for the BLV-infected
sheep; no statistically significant difference by the Student t
test). In contrast, a statistically significant difference (P  0.01
by the two-tailed unpaired Student t test) was observed be-
tween the death rates of B lymphocytes from BLV-infected
and control sheep.
We thus conclude that in BLV-infected sheep, the periph-
eral blood B-lymphocyte population undergoes increased cell
death. This conclusion is supported by the fact that very few
cells labeled with CFSE in the blood and trafficking through
the lymph node are able to express viral capsid antigen p24
(Fig. 5A). The most straightforward interpretation of this ob-
servation is that efficient immune selection is exerted toward
cells spontaneously expressing BLV.
DISCUSSION
Homeostatic regulation of lymphocyte numbers in the pe-
ripheral blood results from a series of physiological factors of
which cell proliferation and death are only partial components.
Indeed, the kinetics of a cell population is also influenced by
recirculation to lymphoid organs, in which proliferation is
thought to primarily occur, at least under normal or chronic
conditions. Our initial experiments based on BrdU kinetics
thus pertained mainly to cells in lymphoid tissues leading to an
apparent discrepancy; i.e., the imbalance created by the net
increase in proliferation in the absence of compensating cell
death was estimated at 7% growth in a day (7). Since this
considerable growth rate was not reflected by an increase in
the corresponding lymphocyte numbers, other regulatory
mechanisms, including a reduction of recirculation through the
lymph node, as well as massive elimination of cells in other
tissues, could play a role. On the basis of CFSE labeling of
peripheral blood leukocytes, we demonstrate here that the
latter mechanism is an important factor during chronic BLV
infection. Collectively, observations deduced from BrdU and
CFSE kinetics can tentatively be summarized in a global model
(Fig. 5B). Quantification of the dynamic parameters by the two
approaches shows that the excess proliferation in lymphoid
FIG. 2. B-cell CFSE kinetics in peripheral blood. (A) CFSE was
injected into the jugular vein of a control sheep (117), and blood was
recovered at different times (before and 1 min, 2 h, and 6 days after
injection) from the other jugular vein. PBMCs were isolated by Percoll
gradient centrifugation, and fluorescence was measured by flow cytom-
etry of 10,000 cells (x axis  CFSE; y axis  number of events).
(B) One BLV-infected (2091) and one control (2147) sheep were
injected intravenously with a bolus of CFSE, and an aliquot of blood
was collected by jugular venipuncture before injection and at 1, 6, or 34
days postinjection. PBMCs were purified, and B cells were labeled with
the anti-IgM 1H4 monoclonal antibody and stained with a phyco-
erythrin conjugate. Finally, 10,000 cells were analyzed by flow cytom-
etry (x axis  CFSE; y axis  B lymphocytes). The percentages of
CFSE B cells within the total B-lymphocyte population are indicated
in the upper right quadrants. (C) Kinetics of the CFSE B-cell pop-
ulation in the peripheral blood of three BLV-infected (2091, 4535, and
4536; solid lines) and three control (2147, 4533, and 4534; dotted lines)
sheep. The arrows indicate key times of CFSE kinetics (day 27 and day
83) at which the percentages of labeled B cells reached baseline levels
in BLV-infected sheep and in the controls, respectively.
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organs can be compensated for by increased cell death in the
peripheral blood. In fact, immunophenotyping of the cell pop-
ulations involved adds another level of complexity. CD11b B
lymphocytes recirculate efficiently via the lymph nodes; cells
lacking this marker are mostly restricted to the peripheral
blood and spleen (14). This is consistent with previous reports
showing that the recirculating subpopulation has the pheno-
type CD11b CD21 L-selectin CD5 and is detected in
efferent lymph (23, 35). Interestingly, expression of CD11b also
specifically correlates with the particular CFSE kinetics ob-
served in BLV-infected sheep (Fig. 3). Since CD11b B lym-
phocytes preferentially accumulate while disease progresses
(5), the increased death rate of this population could appear
paradoxical. However, it should be noted that CFSE kinetics
pertains to CD11b cells exclusively labeled within the periph-
eral blood but not in the white pulp of the spleen. Indeed, cells
do not stain fluorescently in spleen biopsy material isolated at
30 min after CFSE injection (see Fig. S2 in the supplemental
material). We therefore hypothesize that the CD11b B-cell
death in the peripheral blood is compensated for by an excess
in proliferation occurring in the spleen follicles, a parameter
that remains to be precisely quantified in this particular organ.
Since 11.9% of the B cells from the peripheral blood pool
disappear each day in BLV-infected sheep, compared to 5.2%
in controls, the CFSE kinetics reveals a very dynamic process
in a rather chronic disease lasting several months (if not years)
before transformed lymphocytes finally accumulate at the final
leukemic stage. Furthermore, there is also a clear trend toward
excessive proliferation but this difference is not statistically
significant (0.039  0.003 versus 0.029  0.017 in the controls).
Among a series of plausible hypotheses that cannot be formally
excluded, one of the possible models is that the increased
turnover results from an activated immune response directed
toward the virus. Continuous expression of viral antigens could
indeed exacerbate proliferation of virus-reactive immune cells
either directly or via cytokines and thus also potentially BLV-
FIG. 2—Continued.
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FIG. 3. Kinetic analyses of B-cell subsets. At regular time intervals of the CFSE kinetic analysis of three BLV-infected sheep (2091, 4535, and
4536) and three controls (2147, 4333, and 4534) (Fig. 2), PBMCs were labeled with a B-lymphocyte-specific antibody and with a peridinin-
chlorophyll-protein conjugate. The PBMCs were then incubated with monoclonal antibodies directed against L-selectin, CD21, CD5, or CD11b
and with a phycoerythrin conjugate. Finally, 10,000 events of thrice-labeled cells were analyzed by flow cytometry. The percentages of CFSE B
cells expressing L-selectin, CD21, CD5, or CD11b in the corresponding B-lymphocyte subsets were determined at different time intervals (in days).
At day 26, the percentages of CFSE CD11b B cells reached baseline levels in both infected sheep and controls (arrow).
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FIG. 4. Theoretical fit of the model to the CFSE data. The percentages of CFSE B cells (P [black squares]) and the ratio of the MFI of B
CFSE cells to the MFI of B CFSE cells (I [open triangles]) were determined by flow cytometry analyses. The data corresponding to the P and
I values were fitted simultaneously to a mathematical model, yielding theoretical curves.
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infected B lymphocytes. Excessive proliferation of uninfected
B lymphocytes in response to BLV infection has recently been
clearly documented (10). Whether a similar antiviral process is
also responsible for expansion of BLV-infected B cells is un-
known. Arguments against this hypothetical mechanism of in-
direct viral spread include the absence of a selective growth
advantage conferred on infected cells. Why would a viral an-
tigen-specific B cell be preferentially infected by the virus? We
therefore favor a model in which the virus plays an active role
by continuously expressing viral proteins, like that encoded by
the tax oncogene, able to promote cell proliferation. The on-
cogenic potential of Tax, which has been extensively exempli-
fied in numerous systems (13, 17, 26, 30, 32), would favor
replication of the infected cell. Indirectly, permanent tax ex-
pression would also concomitantly stimulate the antiviral im-
mune response, which in turn would clear the infected cells.
Shutoff of viral expression by viral accessory proteins (24)
would then allow a minority of these cells to escape the im-
mune response. Since very few lymphocytes expressing viral
proteins can be directly observed in vivo (18, 19), the frequency
of infected cells surviving the host immune pressure is low.
Also, this process would only marginally affect the very large
majority of infected cells containing a silent virus (or a less
frequently expressed virus). The net outcome of this model
would be global stability of the proviral loads, with some fluc-
tuations of individual clones, as revealed by long-term fol-
low-up of proviral integration sites by ligation-mediated PCR
(20, 21). Although still hypothetical, this model best reconciles
all of the currently available evidence, i.e., the oncogenic po-
tential of Tax (13, 17, 26, 30, 32), the permanent stimulation of
the immune system, the low levels of detectable cells express-
ing viral proteins in vivo, the apparent stability of individual
proviral clones, and the CFSE kinetics reported here.
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FIG. 5. Model summarizing the dynamic parameters studied.
(A) PBMCs from two BLV-infected sheep were isolated from total
blood, and cells were collected in parallel from lymph. Cells were
cultivated for 24 h in RPMI medium supplemented with 10% fetal calf
serum, 2 mM glutamine, and penicillin-streptomycin. B cells and viral
capsid protein p24 were then labeled with specific monoclonal anti-
bodies and analyzed by flow cytometry. The percentages of CFSE B
cells expressing p24 in blood are represented by black bars, and data
from lymph are represented by gray bars. The data are mean values
and standard deviations resulting from more than five samplings taken
over a period of 46 h post CFSE injection. (B) Quantification of
proliferation and death rates in BLV-infected sheep. Excessive prolif-
eration in the lymphoid tissues measured by BrdU incorporation can
be compensated for by an increase in cell death in the peripheral
blood, as deduced from the CFSE kinetics. The percentages shown
represent the proliferation or death rates determined in BLV-infected
or control sheep. **, statistically significant difference (P  0.01) by
the two-tailed unpaired Student t test.










2147 0.049  0.005 0.079  0.008
2152 0.008  0.007 0.022  0.022
4533 0.033  0.005 0.060  0.005
4534 0.026  0.002 0.046  0.004
BLV infected
2091 0.042  0.007 0.113  0.013
2158 0.042  0.006 0.098  0.008
4535 0.037  0.003 0.122  0.010
4536 0.036  0.005 0.144  0.020
Mean value
Uninfected 0.029  0.017 0.052  0.024
BLV infected 0.039  0.003b 0.119  0.019c
a Minimal proliferation and death rates were estimated by fitting a theoretical
model to the CFSE incorporation data. The standard deviations of the individual
parameters reflect the level of confidence in the estimated parameters. Mean
values were calculated for BLV-infected (2091, 2158, 4535, and 4536) and con-
trol (2147, 2152, 4533, and 4534) sheep. The standard deviations of the mean
values reflect the variability within each group. The proliferation rates of the
CFSE-positive B-cell population are statistically similar between the infected
(2091, 2158, 4535, and 4536) and control (2147, 2152, 4533, and 4534) sheep.
However, the death rates of the labeled-B-cell population are statistically signif-
icantly different between the two groups of animals.
b No statistically significant difference by unpaired two-tailed Student t test
(P  0.05).
c Statistically significant difference by unpaired two-tailed Student t test (P 
0.01).
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gium), and C. Howard (Institute for Animal Health, Compton, United
Kingdom).
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